CD19 and leukemia: In addition, another non-randomized study, in which 110 B-ALL patients received CD19 CAR-T therapy and 75 nonrandomly selected patients (73.5%) subsequently received an allo-HSCT, also exhibited that leukemia-free survival (76.9% vs 11.6%; P <.0001; 95% confidence interval [CI], 11.6-108.4) and OS (79.1% vs 32.0%; P <.0001; 95% CI, 0.02-0.22) were significantly better among patients who subsequently received allo-HSCT compared with those receiving CAR T-cell therapy alone (123).